Association of Provider Specialty and Multidisciplinary Care With Hepatocellular Carcinoma Treatment and Mortality - PubMed (original) (raw)

Observational Study

. 2017 Jun;152(8):1954-1964.

doi: 10.1053/j.gastro.2017.02.040. Epub 2017 Mar 7.

Tamar H Taddei 2, Rajni Mehta 2, Kathryn D'Addeo 2, Feng Dai 2, Ayse Aytaman 3, Michelle Baytarian 4, Rena Fox 5, Kristel Hunt 6, David S Goldberg 7, Adriana Valderrama 8, David E Kaplan 9; VOCAL Study Group

Affiliations

Observational Study

Association of Provider Specialty and Multidisciplinary Care With Hepatocellular Carcinoma Treatment and Mortality

Marina Serper et al. Gastroenterology. 2017 Jun.

Abstract

Background & aims: Little is known about provider and health system factors that affect receipt of active therapy and outcomes of patients with hepatocellular carcinoma (HCC). We investigated patient, provider, and health system factors associated with receipt of active HCC therapy and overall survival.

Methods: We performed a national, retrospective cohort study of all patients diagnosed with HCC from January 1, 2008 through December 31, 2010 (n = 3988) and followed through December 31 2014 who received care through the Veterans Administration (128 centers). Outcomes were receipt of active HCC therapy (liver transplantation, resection, local ablation, transarterial therapy, or sorafenib) and overall survival.

Results: In adjusted analyses, receiving care at an academically affiliated Veterans Administration hospital (odds ratio [OR], 1.97; 95% confidence interval [CI], 1.60-2.41) or a multi-specialist evaluation (OR, 1.60; 95% CI, 1.15-2.21), but not review by a multidisciplinary tumor board (OR, 1.19; 95% CI, 0.98-1.46), was associated with a higher likelihood of receiving active HCC therapy. In time-varying Cox proportional hazards models, liver transplantation (hazard ratio [HR], 0.22; 95% CI, 0.16-0.31), liver resection (HR, 0.38; 95% CI, 0.28-0.52), ablative therapy (HR, 0.63; 95% CI, 0.52-0.76), and transarterial therapy (HR, 0.83; 95% CI, 0.74-0.92) were associated with reduced mortality. Subspecialist care by hepatologists (HR, 0.70; 95% CI, 0.63-0.78), medical oncologists (HR, 0.82; 95% CI, 0.74-0.91), or surgeons (HR, 0.79; 95% CI, 0.71-0.89) within 30 days of HCC diagnosis, and review by a multidisciplinary tumor board (HR, 0.83; 95% CI, 0.77-0.90), were associated with reduced mortality.

Conclusions: In a retrospective cohort study of almost 4000 patients with HCC cared for at VA centers, geographic, provider, and system differences in receipt of active HCC therapy are associated with patient survival. Multidisciplinary methods of care delivery for HCC should be prospectively evaluated and standardized to improve access to HCC therapy and optimize outcomes.

Keywords: Liver Cancer; Population; Quality; Risk Factor.

Copyright © 2017 AGA Institute. Published by Elsevier Inc. All rights reserved.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest

The authors disclose no conflicts.

Figures

Figure 1

Figure 1

First HCC-directed therapy received. Percentage of veterans receiving hepatic resection, liver transplantation, ablative therapies (radio-frequency, microwave, or cryo-ablation), transarterial therapies (bland, chemo- or radio-embolization), hospice care, and no active therapy as first intervention stratified by BCLC stage.

Figure 2

Figure 2

Unadjusted median survival stratified by BCLC stage. Kaplan-Meier survival analysis of 5-year overall survival shown.

Figure 3

Figure 3

Correlation between receipt of active HCC therapy and overall survival at the regional level. Spearman correlation of the proportion of patients receiving active HCC therapy (defined as resection, transplantation, ablation, transarterial therapy, or sorafenib) (“Proportion treated”) and median overall survival (OS) in months grouped by Veterans Integrated Service Network region. The diameter of each circle is proportional to the number of HCC cases in each Veterans Integrated Service Network.

Comment in

References

    1. McGlynn KA, London WT. The global epidemiology of hepatocellular carcinoma: present and future. Clin Liver Dis. 2011;15:223–243. vii–x. - PMC - PubMed
    1. Njei B, Rotman Y, Ditah I, et al. Emerging trends in hepatocellular carcinoma incidence and mortality. Hepatology. 2015;61:191–199. - PMC - PubMed
    1. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0 Cancer incidence and mortality worldwide: IARC CancerBase No. 11. Lyon, France: International Agency for Research on Cancer; 2013. Available at: http://globocan.iarc.fr/ (accessed June 24, 2016)
    1. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379:1245–1255. - PubMed
    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5–29. - PubMed

Publication types

MeSH terms

LinkOut - more resources